Treatment and Survival for Unresectable Pancreatic Adenocarcinoma in Queensland, Australia, 2018–2022
Cancer Medicine · 2025
DOI: 10.1002/cam4.71226 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Danny R Youlden und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Alliance Queensland, Metro South Health, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The three main chemotherapy regimens for people with unresectable pancreatic cancer include modified FOLFIRINOX (comprising oxaliplatin, irinotecan and fluorouracil, denoted mFFX), gemcitabine with nab‐paclitaxel (GnP), and single‐agent gemcitabine (GEM). We explored characteristics associated with the type of chemotherapy and variations in survival. Materials and Methods Records for people with unresected pancreatic adenocarcinoma between 2018 and 2022 treated with first‐line mFFX, GnP or GEM were extracted from the population‐based Queensland Oncology Repository. Multivariable Poisson models were fitted to determine factors associated with each type of chemotherapy, expressed as relative likelihoods (RLs). Variations in three‐year observed survival were assessed using flexible parametric modelling and reported in terms of adjusted excess mortality hazard ratios (HRs).
Results
Of the 766 people in the study cohort, 59% were treated with GnP, 27% with mFFX, and 15% with GEM. After adjustment, treatment with mFFX was far more likely in selected private facilities compared to public hospitals (RL = 2.33, 95% CI 1.84–2.96), whereas the GEM regimen was used more often for those from outer regional/remote areas (RL = 2.20 compared to people living in major cities, 95% CI 1.45–3.34; p < 0.001). Three‐year survival was very poor at just 5% (95% CI 3%–7%). Nonetheless, adjusted mortality was higher for GnP (HR = 1.30, 95% CI 1.07–1.59) and GEM (HR = 1.53, 95% CI 1.17–2.01) compared to mFFX.
Conclusions
Apart from clinical indications, there should be equity in the treatment received for unresectable pancreatic cancer. Our results suggest, however, that where a person lives and the type of facility at which they are treated may influence their chemotherapy regimen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Alliance Queensland, Metro South Health, Brisbane, Queensland, Australia.
- Adem Crosby Cancer Centre, Department of Medical Oncology, Division of Cancer Care Services, Sunshine Coast University Hospital, Birtinya, Queensland, Australia.
- School of Medicine and Dentistry, Griffith University, Birtinya, Queensland, Australia.
- Centre for Bioinnovation, University of the Sunshine Coast, Sippy Downs, Queensland, Australia.
ORCID-Profile: Danny R Youlden, Michael J Allen
Zitieren
APA
Youlden, D. R., Chan, B. A., Clark, J., Donoghue, V. K., & Allen, M. J. (2025). Treatment and Survival for Unresectable Pancreatic Adenocarcinoma in Queensland, Australia, 2018–2022. Cancer Medicine. https://doi.org/10.1002/cam4.71226
Vancouver
Youlden DR, Chan BA, Clark J, Donoghue VK, Allen MJ. Treatment and Survival for Unresectable Pancreatic Adenocarcinoma in Queensland, Australia, 2018–2022. Cancer Medicine. 2025. doi:10.1002/cam4.71226
BibTeX
@article{Youlden2025,
author = {Youlden, Danny R and Chan, Bryan A and Clark, Jon and Donoghue, Victoria K and Allen, Michael J},
title = {Treatment and Survival for Unresectable Pancreatic Adenocarcinoma in Queensland, Australia, 2018–2022},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71226}
}
EUVIMED